Specifica, a Q2 Solutions Company, develops and delivers exceptional antibody libraries to support drug discovery. Our patented Generation 3 platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering.
Specifica antibody libraries deliver:
Fast Discovery
Specifica provides high affinity antibodies with excellent developability and high diversity, saving time and money during development.
High Affinity
60% of antibodies from platform have affinities below 10nM
20% are in the sub-nanomolar range
Excluding pMHC selections, more than 75% of campaigns generate at least 1 sub-nanomolar antibody
High Diversity
AbXtract machine learning module groups antibodies into 10 to 1,000 distinct clusters
Provides antibodies against a wide variety of target epitopes with the potential for differential biology
Developability
Sequence liabilities are purged from all CDRs except HCDR3
More than 80% of antibodies have no measurable biophysical liabilities
Our antibodies behave as well as the best therapeutic antibodies
In examining two-group differential analysis, it is apparent that different statistical methods can yield very different results even given the same RNA-Seq input data. In particular, we have...
With more than 25 years of experience, Rules-Based Medicine, a Q2 Solutions company develops, validates and manufactures its assays with integrity and commitment for the most reliable, reproducible...
By Chloe Ackaert, Jana Schockaert, Aurelie Mazy, Martijn Vlaming, and Sofie PattynPresented at the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024 Bispecifics...
